Letter to the Editor Re: Ahn DH, Krishna K, Blazer M, . “A modified regimen of biweekly gemcitabine and -paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.” https://doi.org/10.1177/1758834016676011
Main Authors: | Daniel D Von Hoff, Markus F Renschler |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-06-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758834017699772 |
Similar Items
-
doi: https://doi.org/10.15407/ubj88.02.073
by: N. Ya. Golovenko, et al.
Published: (2016-04-01) -
Corrigendum to “Pazopanib in the treatment of advanced renal cell carcinoma” by David Cella and Jennifer L. Beaumont, , 2016, Vol. 8(1) 61–69. DOI: 10.1177/1756287215614236
Published: (2016-08-01) -
Comment to: Interobserver variability in the assessment of the clinical severity of superficial venous insufficiency by Sinabulya H, Holmberg A, Blomgren L. Phlebology 2013. [Epub ahead of print] doi:10.1177/0268355513515474
by: Stefano Ricci
Published: (2014-11-01) -
Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck
by: Ammar Sukari, et al.
Published: (2015-04-01) -
A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer
by: Spinelli Gian, et al.
Published: (2006-05-01)